Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement - Seite 2

Aware: Pioneering Breast Health Self-Exams
Aware is an innovative, FDA cleared device that increases tactile sensitivity during breast self-exams. By making it easier for women to detect changes in their breast tissue, Aware can play a crucial role in breast exams. Despite the lack of family history in over 70% of diagnosed cases, early detection through tools like Aware significantly enhances the chances of successful treatment.

Broader Health Impacts and Company’s Commitment
Zack Irani, CEO of Biomerica, commented, "This partnership signifies a leap forward in our commitment to screening. By joining forces with one of the UAE’s top healthcare companies, we are not just distributing products but also supporting a shift towards proactive health management in the Middle East. The inclusion of EZ Detect in insurance coverage by the Dubai government exemplifies this shift and paves the way for greater health security. We are working to do the same with the Aware product."

Colorectal Cancer
Colorectal cancer is a prevalent and potentially life-threatening condition that affects millions of individuals worldwide. According to the World Health Organization (WHO), in 2020 alone, more than 1.9 million new cases of colorectal cancer and more than 930,000 deaths due to colorectal cancer were estimated to have occurred worldwide. The organization estimates that colorectal cancer is the third most common cancer worldwide and is the second leading cause of cancer-related death worldwide. Colorectal cancer is the second most common cause of cancer death in the UAE ^[1].

In a study performed by Johns Hopkins University, EZ Detect was preferred 10 to 1 by patients over another fecal occult blood test. Published studies have also indicated that the best colorectal screening test is “the one that gets it done” ^[2]. Other colorectal screening tests require handling of the stool and sending the stool sample to a lab for processing, which can prove cumbersome. Because of the unpleasant difficulties of handling and mailing stool samples, a high percentage of these competing tests are never completed by patients ^[3]. This potentially increases the risk for delayed detection of colorectal cancer.